VISUMPharma Inc. develops pharmaceuticals targeting degenerative neurological diseases, specifically focusing on Parkinson's and Alzheimer's, utilizing a novel oncology-based approach. The company aims to provide healthcare professionals with effective treatment options for complex conditions such as cancers and adult-onset motor neuron disease.
Funding
Funding not disclosed
Founders
Product
Problem
Degenerative neurological diseases like Parkinson's and Alzheimer's present significant challenges due to their complex pathophysiology and limited treatment options. Current therapies often provide only symptomatic relief, failing to address the underlying disease mechanisms or halt disease progression. The need for disease-modifying treatments remains unmet.
Solution
VISUMPharma Inc. is developing pharmaceuticals for degenerative neurological diseases, including Parkinson's and Alzheimer's, by leveraging insights from oncology research. This approach aims to identify and target common molecular pathways involved in both cancer and neurodegeneration. By repurposing or adapting oncology-based strategies, VISUMPharma seeks to develop novel therapies that can modify disease progression and improve patient outcomes. The company's focus is on providing healthcare professionals with effective treatment options for these complex and debilitating conditions.
Target Audience
The primary target audience includes healthcare professionals, such as neurologists and geriatricians, who treat patients with Parkinson's and Alzheimer's disease, as well as the patients themselves.
Features
- Utilizes an oncology-based approach to target degenerative neurological diseases.
- Focuses on identifying common molecular pathways in cancer and neurodegeneration.
- Developing pharmaceuticals for Parkinson's and Alzheimer's disease.
- Aims to modify disease progression rather than just treating symptoms.